Although the incidence of eye disorders was greater in this PMS than in COLUMBUS, the phase III trial excluded patients with a history or symptoms of retinal vein occlusion (RVO) or risk factors for RVO (e.g., uncontrolled glaucoma or high intraocular pressure, hyperviscosity or hypercoagulable syndromes), and patients with a history of treatment with BRAF or MEK inhibitors, which were SS in the COLUMBUS trial [8]. This evidence concerns the gene MAP2K7 and glaucoma.